SEC Company Response from AVITA Medical, Inc. (RCEL, AVHHL) (CIK 0001762303) (RCEL) — Sep 26, 2019
AVITA Medical, Inc. (RCEL, AVHHL) (CIK 0001762303)
Date: Sept. 26, 2019 · CIK: 0001762303 · Accession: 0001193125-19-255962
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39059, 333-233853
Letter
AVITA MEDICAL LTD.
Level 7, 330 Collins Street
Melbourne VIC 3000 Australia
September 26, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Re: Avita Medical Limited (CIK No. 0001762303)
Registration Statement on Form 20-F
Initially Submitted July 19, 2019
File No. 001-39059
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Avita Medical Limited (the “Company”) hereby respectfully requests acceleration of the effective date of the Company’s registration statement on Form 20-F, initially submitted to the U.S. Securities and Exchange Commission (the “Commission”) on July 19, 2019 and filed with the Commission on September 19, 2019 (as amended, the “20-F Registration Statement”), so that it may become effective at 4:00 p.m., Eastern Time, on September 27, 2019, or as soon thereafter as practicable.
The Company understands that The Bank of New York Mellon, as Depositary, has requested that the registration statement on Form F-6, submitted to the Commission on September 19, 2019 (File No.: 333-233853) be declared effective concurrently with the 20-F Registration Statement, and pursuant to Rule 461 promulgated under the Securities Act, the Company concurs with that request.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact me at 661-367-9161 or via e-mail at troony@avitamedical.com or our outside legal counsel from K&L Gates, LLP, Christopher Cunningham at 206-370-7639 or via email at chris.cunningham@klgates.com. The Company hereby authorizes each of Mr. Rooney and Mr. Cunningham (and either one of them) to orally modify or withdraw this request for acceleration.
Respectfully,
Avita Medical Limited
Show Raw Text
CORRESP 1 filename1.htm CORRESP AVITA MEDICAL LTD. Level 7, 330 Collins Street Melbourne VIC 3000 Australia September 26, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Avita Medical Limited (CIK No. 0001762303) Registration Statement on Form 20-F Initially Submitted July 19, 2019 File No. 001-39059 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Avita Medical Limited (the “Company”) hereby respectfully requests acceleration of the effective date of the Company’s registration statement on Form 20-F, initially submitted to the U.S. Securities and Exchange Commission (the “Commission”) on July 19, 2019 and filed with the Commission on September 19, 2019 (as amended, the “20-F Registration Statement”), so that it may become effective at 4:00 p.m., Eastern Time, on September 27, 2019, or as soon thereafter as practicable. The Company understands that The Bank of New York Mellon, as Depositary, has requested that the registration statement on Form F-6, submitted to the Commission on September 19, 2019 (File No.: 333-233853) be declared effective concurrently with the 20-F Registration Statement, and pursuant to Rule 461 promulgated under the Securities Act, the Company concurs with that request. Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact me at 661-367-9161 or via e-mail at troony@avitamedical.com or our outside legal counsel from K&L Gates, LLP, Christopher Cunningham at 206-370-7639 or via email at chris.cunningham@klgates.com. The Company hereby authorizes each of Mr. Rooney and Mr. Cunningham (and either one of them) to orally modify or withdraw this request for acceleration. Respectfully, Avita Medical Limited By: /s/ Timothy Rooney Name: Timothy Rooney Title: Acting Chief Financial Officer cc: Christopher Cunningham (K&L Gates LLP) Jonathan Miner (K&L Gates LLP)